Prostate Cancer
Tumor architecture and emergence of strong genetic alterations are bottlenecks for clonal evolution in primary prostate cancer.
November 25, 2024
Using a behaviour-change approach to support uptake of population genomic screening and management options for breast or prostate cancer.
November 25, 2024
Transcription and DNA replication collisions lead to large tandem duplications and expose targetable therapeutic vulnerabilities in cancer.
November 25, 2024
PSMA Radiotheranostics in Prostate Cancer: Principles, Practice, and Future Prospects.
November 25, 2024
Association of Race and Area of Deprivation Index with Prostate Cancer Incidence and Lethality.
November 25, 2024
Cost-effectiveness analysis of additional local prostate radio therapy in metastatic prostate cancer from a medicare perspective.
November 25, 2024
Projected Outcomes of Reduced-Biopsy Management of Grade Group 1 Prostate Cancer: Implications for Relabeling.
November 22, 2024
The Association of Where Patients with Prostate Cancer Live and Receive Care on Racial Treatment Inequities.
November 22, 2024
Increased translation driven by non-canonical EZH2 creates a synthetic vulnerability in enzalutamide-resistant prostate cancer.
November 22, 2024
Patients Can Administer Mobile Audio Recordings to Increase Knowledge in Advanced Prostate Cancer.
November 22, 2024